Ensol Biosciences (XKRX:140610) Interest Expense : ₩-1,017 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ensol Biosciences's interest expense for the six months ended in Dec. 2024 was ₩ -1,017 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-1,017 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ensol Biosciences's Operating Income for the six months ended in Dec. 2024 was ₩ -5,072 Mil. Ensol Biosciences's Interest Expense for the six months ended in Dec. 2024 was ₩ -1,017 Mil. Ensol Biosciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ensol Biosciences Interest Expense Historical Data

The historical data trend for Ensol Biosciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Interest Expense Chart

Ensol Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-127.26

-316.44

-764.10

-1,131.24

-1,016.63

Ensol Biosciences Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Interest Expense	Get a 7-Day Free Trial						-127.26	-316.44	-764.10	-1,131.24	-1,016.63

Ensol Biosciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-1,017 Mil.

Ensol Biosciences (XKRX:140610) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ensol Biosciences's Interest Expense for the six months ended in Dec. 2024 was ₩-1,017 Mil. Its Operating Income for the six months ended in Dec. 2024 was ₩-5,072 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2024 was ₩155 Mil.

Ensol Biosciences's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Ensol Biosciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Ensol Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036

Website

http://www.ensolbio.co.kr

Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences Headlines

No Headlines